Home LiteratureArticle Details
PMID: 10934535 Published · ppublish English Journal Article

Recombinant vaccinia viruses. Design, generation, and isolation.

Molecular biotechnology ·Vol. 13 ·No. 3 ·1999-12-15 ·Pages 223-45

Broder CC, Earl PL

Abstract

The technologies of recombinant gene expression have greatly enhanced the structural and functional analyses of genetic elements and proteins. Vaccinia virus, a large double-stranded DNA virus and the prototypic and best characterized member of the poxvirus family, has been an instrumental tool among these technologies and the recombinant vaccinia virus system has been widely employed to express genes from eukaryotic, prokaryotic, and viral origins. Vaccinia virus is also the prototype live viral vaccine and serves as the basis for well established viral vectors which have been successfully evaluated as human and animal vaccines for infectious diseases and as anticancer vaccines in a variety of animal model systems. Vaccinia virus technology has also been instrumental in a number of unique applications, from the discovery of new viral receptors to the synthesis and assembly of other viruses in culture. Here we provide a simple and detailed outline of the processes involved in the generation of a typical recombinant vaccinia virus, along with an up to date review of relevant literature.

MeSH Terms
Animals Genetic Vectors Humans Microbiological Techniques Recombination, Genetic Transfection Vaccinia virus Viral Vaccines
Chemicals
Viral Vaccines
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Broder C C
Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA.
Earl P L
References (85)
85 references, click to expand
  1. A PCR-based method for manipulation of the vaccinia virus genome that eliminates the need for cloning.
    Biotechniques. 1992 Nov;13(5):764-71 PMID: 1418979
  2. Construction of chimeric vaccinia viruses by molecular cloning and packaging.
    Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):9977-81 PMID: 1438247
  3. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.
    Nature. 1987 Oct 8-14;329(6139):545-6 PMID: 3498904
  4. A dominant selectable marker for the construction of recombinant poxviruses.
    Gene. 1988 May 15;65(1):123-8 PMID: 2840353
  5. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    J Infect Dis. 1999 Jun;179(6):1345-51 PMID: 10228053
  6. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs.
    Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15400-4 PMID: 8986823
  7. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.
    EMBO J. 1987 Nov;6(11):3379-84 PMID: 2828027
  8. An infectious clone of human parainfluenza virus type 3.
    J Virol. 1997 Jun;71(6):4272-7 PMID: 9151814
  9. Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.
    AIDS Res Hum Retroviruses. 1996 Mar 20;12(5):407-8 PMID: 8882320
  10. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Dev Biol Stand. 1994;82:55-63 PMID: 7958483
  11. The hygromycin-resistance-encoding gene as a selection marker for vaccinia virus recombinants.
    Gene. 1991 Nov 15;107(2):307-12 PMID: 1660832
  12. Vaccinia virus: a selectable eukaryotic cloning and expression vector.
    Proc Natl Acad Sci U S A. 1982 Dec;79(23):7415-9 PMID: 6296831
  13. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.
    J Virol. 1984 Mar;49(3):857-64 PMID: 6321770
  14. E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.
    Biotechniques. 1995 Sep;19(3):352-4, 356 PMID: 7495543
  15. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
    Nat Med. 1998 Apr;4(4):397-402 PMID: 9546783
  16. Inducible gene expression from vaccinia virus vectors.
    Virology. 1990 Jul;177(1):239-50 PMID: 2191497
  17. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
    Vaccine. 1994 Aug;12(11):1032-40 PMID: 7975844
  18. Isolation and handling of recombinant vaccinia viruses.
    Methods Mol Biol. 1992;8:235-48 PMID: 21390716
  19. Poxviruses as expression vectors.
    Curr Opin Biotechnol. 1997 Oct;8(5):573-7 PMID: 9353230
  20. Vaccinia virus: a tool for research and vaccine development.
    Science. 1991 Jun 21;252(5013):1662-7 PMID: 2047875
  21. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence.
    J Virol. 1999 Jun;73(6):5001-9 PMID: 10233962
  22. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.
    J Gen Virol. 1998 Feb;79 ( Pt 2):347-52 PMID: 9472619
  23. Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vectors.
    J Virol. 1990 Oct;64(10):4851-7 PMID: 2204724
  24. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.
    J Virol. 1990 May;64(5):2448-51 PMID: 2182912
  25. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts.
    J Gen Virol. 1995 Dec;76 ( Pt 12):2957-62 PMID: 8847500
  26. Poxvirus vectors: cytoplasmic expression of transferred genes.
    Curr Opin Genet Dev. 1993 Feb;3(1):86-90 PMID: 8453278
  27. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.
    Mol Cell Biol. 1985 Aug;5(8):1918-24 PMID: 3018537
  28. Applications of pox virus vectors to vaccination: an update.
    Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53 PMID: 8876138
  29. Compact, synthetic, vaccinia virus early/late promoter for protein expression.
    Biotechniques. 1997 Dec;23(6):1094-7 PMID: 9421642
  30. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.
    Nature. 1987 Nov 19-25;330(6145):259-62 PMID: 3118219
  31. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.
    J Gen Virol. 1991 May;72 ( Pt 5):1031-8 PMID: 2033387
  32. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins.
    Nucleic Acids Res. 1990 Jul 25;18(14):4285-6 PMID: 2377486
  33. SP6 RNA polymerase containing vaccinia virus for rapid expression of cloned genes in tissue culture.
    Biotechniques. 1993 Feb;14(2):222-4 PMID: 8431286
  34. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.
    J Virol. 1992 May;66(5):2934-42 PMID: 1560532
  35. A modified method for isolation of recombinant vaccinia virus.
    Biotechniques. 1994 Jul;17(1):40, 42 PMID: 7946309
  36. The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s).
    Virology. 1993 Mar;193(1):483-91 PMID: 8438583
  37. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.
    AIDS Res Hum Retroviruses. 1995 Aug;11(8):909-20 PMID: 7492438
  38. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages.
    Virology. 1999 Jun 20;259(1):1-6 PMID: 10364484
  39. Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids.
    J Virol. 1996 Aug;70(8):5016-24 PMID: 8764008
  40. Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors.
    Virology. 1992 Sep;190(1):522-6 PMID: 1529553
  41. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
    J Virol. 1998 May;72(5):4170-82 PMID: 9557706
  42. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
    Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 PMID: 3095828
  43. Transient dominant selection of recombinant vaccinia viruses.
    J Virol. 1990 Jun;64(6):3108-11 PMID: 2159565
  44. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.
    Vaccine. 1993;11(1):43-53 PMID: 8427036
  45. Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons.
    J Comp Neurol. 1996 Oct 28;374(4):481-92 PMID: 8910730
  46. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes.
    Proc Natl Acad Sci U S A. 1987 Sep;84(18):6417-21 PMID: 3476956
  47. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.
    Mol Cell Biol. 1985 Dec;5(12):3403-9 PMID: 3939316
  48. Requirements for optimal expression of secreted and nonsecreted recombinant proteins in vaccinia virus systems.
    Protein Expr Purif. 1995 Oct;6(5):559-69 PMID: 8535147
  49. NYVAC: a highly attenuated strain of vaccinia virus.
    Virology. 1992 May;188(1):217-32 PMID: 1566575
  50. Vaccinia virus vectors for gene expression.
    Curr Opin Biotechnol. 1991 Oct;2(5):713-7 PMID: 1367723
  51. Inducer-dependent conditional-lethal mutant animal viruses.
    Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1511-5 PMID: 1899929
  52. Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework.
    J Virol. 1987 Feb;61(2):516-25 PMID: 3027380
  53. A comparison of regulatory features in primate lentiviruses.
    AIDS Res Hum Retroviruses. 1992 Mar;8(3):387-93 PMID: 1315144
  54. Dominant host range selection of vaccinia recombinants by rescue of an essential gene.
    Virology. 1998 Sep 15;249(1):160-6 PMID: 9740787
  55. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
    J Virol. 1993 Feb;67(2):913-26 PMID: 8419649
  56. Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.
    J Virol. 1998 Jul;72(7):5707-16 PMID: 9621029
  57. Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses.
    Virology. 1990 Oct;178(2):626-30 PMID: 2219714
  58. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
    AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):461-70 PMID: 10195756
  59. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
    Immunol Today. 1997 Apr;18(4):175-82 PMID: 9136454
  60. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection.
    Vaccine. 1999 Jan 28;17(4):308-18 PMID: 9987168
  61. Construction and characterization of vaccinia direct ligation vectors.
    Virology. 1997 Nov 24;238(2):444-51 PMID: 9400616
  62. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
    Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51 PMID: 1438287
  63. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes.
    Vaccine. 1999 Jan 21;17(3):261-8 PMID: 9987162
  64. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):9004-8 PMID: 7568061
  65. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors.
    J Virol. 1988 Jun;62(6):1849-54 PMID: 3130492
  66. Recombinant protein synthesis in Chinese hamster ovary cells using a vaccinia virus/bacteriophage T7 hybrid expression system.
    J Biol Chem. 1996 Jul 12;271(28):16962-6 PMID: 8663285
  67. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    J Virol. 1994 May;68(5):3015-26 PMID: 7512157
  68. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.
    J Leukoc Biol. 1995 Jul;58(1):1-13 PMID: 7616101
  69. Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus.
    Arch Virol. 1998;143(3):467-74 PMID: 9572548
  70. Manipulation of vaccinia virus vectors.
    Methods Mol Biol. 1991;7:129-46 PMID: 21416353
  71. Rescue of measles virus using a replication-deficient vaccinia-T7 vector.
    J Virol Methods. 1997 Feb;64(1):57-64 PMID: 9029530
  72. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.
    Mol Cell Biol. 1987 Jul;7(7):2538-44 PMID: 3112559
  73. Rapid and efficient recovery of Sendai virus from cDNA: factors influencing recombinant virus rescue.
    J Virol Methods. 1998 Nov;75(1):47-58 PMID: 9820574
  74. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
    Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 PMID: 8876137
  75. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
    Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6773-7 PMID: 7624318
  76. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.
    J Virol. 1989 Sep;63(9):3829-36 PMID: 2547999
  77. Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.
    Gene. 1994 May 16;142(2):167-74 PMID: 8194748
  78. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  79. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.
    Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927-31 PMID: 6289324
  80. Selection of recombinant vaccinia viruses on the basis of plaque formation.
    Gene. 1995 Jun 9;158(2):157-62 PMID: 7607536
  81. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.
    Virology. 1997 Nov 24;238(2):198-211 PMID: 9400593
  82. Successful pseudorabies vaccination in maternally immune piglets using recombinant vaccinia virus vaccines.
    Res Vet Sci. 1997 May-Jun;62(3):281-5 PMID: 9300549
  83. Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2549-53 PMID: 2649884
  84. Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants.
    J Virol. 1989 Feb;63(2):997-1001 PMID: 2911129
  85. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
    J Virol. 1996 Jun;70(6):3741-52 PMID: 8648709
Article Info
Journal
Molecular biotechnology
Abbr.
Mol Biotechnol
ISSN
1073-6085
DOI
10.1385/MB:13:3:223
Published
1999-12-15
Pages
223-45
Language
English
Region
United States
NLM ID
9423533
Subset
IM
External Links
PubMed source DOI: 10.1385/MB:13:3:223 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2